However, data are rudimentary and even contradictory: in GH-treated growth-deficient children altered metabolic parameters including TNF-α levels are reported e.g., [81], and modulation of cytokines by GH at high doses is suggested to be involved in adverse consequences in critically ill patients, such as septic shock and uncontrolled infections [82]. The gene discussed is GH1; the disease is infection.